Mahmoud Abdelnabi is a Cardiology physician. OpenAlex indexes 284 publications with 1,369 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 852595499
Telephone
480-301-8000Provider last certified this registry record 4 Sept 2024.
Clinical trials
- Thrombus Aspiration in Heavy Thrombus Burden Acute ST-elevation Myocardial Infarction
Sponsor: The Young Investigator Group of Cardiovascular Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20251 payment
- Mallinckrodt Hospital Products Inc.Program year20251 payment
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
52.7%Statin30.4%Atorvastatin Calcium53%Rosuvastatin Calcium47%Part D<11 patientsLoop diuretic11.6%Furosemide100%Part D<11 patients+ 1 more class in this area
Nervous system
23.2%SNRI12.5%Duloxetine Hcl100%Part D<11 patientsSSRI10.7%Sertraline Hcl100%Part D<11 patientsRespiratory
13.4%beta2-Adrenergic Agonist13.4%Albuterol Sulfate Hfa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis
European Heart Journal - Cardiovascular Pharmacotherapy
2025 - Sex-based differences in patients with Loeys-Dietz syndrome: An analysis of arteriopathies and surgical interventions
International Journal of Cardiology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”